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Abstract
Background: Cell-based therapy shows promise in treating peripheral arterial disease (PAD); however, the optimal cell type
and long-term efficacy are unknown. In this study, we identified a novel subpopulation of adult progenitor cells positive for
CD34 and M-cadherin (CD34
+/M-cad
+ BMCs) in mouse and human bone marrow. We also examined the long-lasting
therapeutic efficacy of mouse CD34
+/M-cad
+ BMCs in restoring blood flow and promoting vascularization in an
atherosclerotic mouse model of PAD.
Methods and Findings: Colony-forming cell assays and flow cytometry analysis showed that CD34
+/M-cad
+ BMCs have
hematopoietic progenitor properties. When delivered intra-arterially into the ischemic hindlimbs of ApoE
2/2 mice, CD34
+/
M-cad
+ BMCs alleviated ischemia and significantly improved blood flow compared with CD34
+/M-cad
2 BMCs, CD34
2/M-
cad
+ BMCs, or unselected BMCs. Significantly more arterioles were seen in CD34
+/M-cad
+ cell-treated limbs than in any
other treatment group 60 days after cell therapy. Furthermore, histologic assessment and morphometric analyses of
hindlimbs treated with GFP
+ CD34
+/M-cad
+ cells showed that injected cells incorporated into solid tissue structures at 21
days. Confocal microscopic examination of GFP
+ CD34
+/M-cad
+ cell-treated ischemic legs followed by immunostaining
indicated the vascular differentiation of CD34
+/M-cad
+ progenitor cells. A cytokine antibody array revealed that CD34
+/M-
cad
+ cell-conditioned medium contained higher levels of cytokines in a unique pattern, including bFGF, CRG-2, EGF, Flt-3
ligand, IGF-1, SDF-1, and VEGFR-3, than did CD34
+/M-cad
2 cell-conditioned medium. The proangiogenic cytokines secreted
by CD34
+/M-cad
+ cells induced oxygen- and nutrient-depleted endothelial cell sprouting significantly better than CD34
+/M-
cad
2 cells during hypoxia.
Conclusion: CD34
+/M-cad
+ BMCs represent a new progenitor cell type that effectively alleviates hindlimb ischemia in
ApoE
2/2 mice by consistently improving blood flow and promoting arteriogenesis. Additionally, CD34
+/M-cad
+ BMCs
contribute to microvascular remodeling by differentiating into vascular cells and releasing proangiogenic cytokines and
growth factors.
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Introduction
Peripheral arterial disease (PAD) is an atherosclerotic disease
that results in insufficient blood flow to the lower extremities [1,2].
The incidence of PAD, which affects 8 to 12 million Americans, is
rapidly increasing, commensurate with the rapid rise in the elderly
population [3]. The 2 major clinical stages of PAD are (chronic)
intermittent claudication and critical limb ischemia, which can
result in loss of the ischemic limb, if not rapidly relieved [4,5].
Conventional interventional therapy in patients with PAD often
results in only partial or short-term correction of lower extremity
ischemia. Thus, alternative approaches have been developed,
including the local intramuscular injection of autologous adult
bone marrow stem/progenitor cells (BMCs) [6,7,8]. BMCs engraft
into the ischemic target tissues to varying degrees and may
alleviate ischemic symptoms [6,9]. Thus, autologous BMC
transplantation has the potential to be a safe alternative treatment
strategy for patients with critical limb ischemia for whom current
treatment options are not effective [10,11,12,13]. However, initial
clinical reports indicated that the significant benefits of BMC
therapy are often of limited duration, possibly due to a sharp
reduction in the number of locally engrafted progenitor cells early
after BMC transplantation [12,14,15]. Reduced survival or failed
development of transplanted cells may be due in part to cellular
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supporting capillary network in ischemic tissues [14,16]. The
benefits of cell therapy could be strengthened if a donated
progenitor cell population retained enriched angiogenic potential
and created a pro-angiogenic milieu upon reaching the ischemic
area. Thus, these cells would initiate microvessel formation by
directly differentiating into vascular cells and by stimulating
residual progenitor cell proliferation, mobilization, and engraft-
ment to salvage the compromised tissue.
Accumulating evidence indicates that paracrine action is the
predominant mechanism by which progenitor cells contribute to
vascular repair and regeneration in ischemic vascular diseases
[17,18]. Experimental reports have shown that conditioned
medium (CM) from bone marrow cell cultures contains angiogenic
factors, enzymes, and pro-inflammory cytokines that support new
blood vessel formation and matrix degradation [19]. However,
bone marrow contains a broad array of progenitor and mature
cells [20,21,22], and the cell type with maximal therapeutic
benefits has yet to be identified. Therefore, we seek to identify an
optimal bone marrow progenitor cell population that supports
extensive vascular regeneration in hindlimb ischemia.
In the present study, we have identified and characterized a
population of adult mouse BMCs expressing both CD34 and M-
cadherin surface molecules (CD34
+/M-cad
+ BMCs), and we have
assessed the ability of CD34
+/M-cad
+ BMCs to reduce ischemia in
a hypercholesterolemic mouse (ApoE
2/2) hindlimb model during
a 60-day postoperative time course. Specifically, we examined the
ability to restore blood flow and the arteriogenic potential of
CD34
+/M-cad
+ BMCs and 3 other related populations: unselect-
ed BMCs, a CD34
+/Mcad
2 BMC fraction, and a CD34
2/M-
cad
+ BMC fraction. In addition, we showed the multilineage
proliferative potential as well as vascular differentiation of CD34
+/
M-cad
+ BMCs and assessed the paracrine effects of CD34
+/M-
cad
+ BMC CM, including its ability to promote endothelial
angiogenesis under hypoxia.
Materials and Methods
Mouse Ischemic Hindlimb Model and Bone Marrow Cell
Transplantation
The University of Texas Health Science Center Animal Welfare
Committee guidelines were followed throughout all animal
experiments. Mouse BMCs were collected as previously described
[23]. ApoE
2/2 mice (8–15 months old) served as BMC recipients
and were anesthetized by isofluorane inhalation (2–5% isofluorane
in oxygen) during surgery. By 8 months of age, ApoE
2/2 mice
develop atherosclerotic vascular lesions in peripheral vessels when
fed regular chow [24,25]. Hindlimb ischemia was created by
unilateral surgical ligation by using 2 adjacent sutures to interrupt
the proximal left femoral artery and vein [23]. To examine the cell
population of BMCs that home to ischemic tissues, 2.5610
7
unselected BMCs from adult transgenic mice (6–8 weeks old)
that expressed an enhanced green fluorescent protein (GFP
+)
variant were injected intraarterially into the ischemic hindlimb of
ApoE
2/2 mice (n=5) just distal to the ligation site. At 7 days after
cell delivery, mice were euthanized, and leg samples were
obtained. Additionally, age-matched ApoE
2/2 mice (n=5 per
group) were divided into 2 groups to evaluate the engraftment of
CD34
+/M-cad
+ BMCs as compared to CD34
+/M-cad
2 BMCs.
Ischemia was similarly established, and a single dose of 3610
5
GFP
+ CD34
+/M-cad
+ BMCs or CD34
+/M-cad
2 BMCs was
intraarterially injected into the ischemic hindlimbs; these mice
were euthanized at 21 days after cell treatment. Finally, we
randomly divided a separate group of ApoE
2/2 mice into 4 cell
treatment groups (n=9 to 11 mice/group). After undergoing the
same surgical procedure described above, the mice received
intraarterial injections in the femoral artery of 1 of the following
cell types (3610
5 cells) isolated from C57BL6/J mice (6–8 weeks
old): unselected BMCs, CD34
+/M-cad
+ BMCs, CD34
+/M-cad
2
BMCs, or CD34
2/M-cad
+ BMCs. Mice were euthanized, and leg
samples were obtained at 60 days after cell treatment. No
immunosuppressant therapy was used during the study.
Flow Cytometric Analysis and Fluorescence-activated Cell
Sorting (FACS)
Freshly isolated BMCs were incubated with fluorescein (FITC)-
conjugated anti-mouse CD34 (eBioscience, San Diego, CA), and/
or a monoclonal anti-M-cadherin antibody (BD Biosciences, San
Diego, CA) for 30 min at 4uC, followed by an additional
incubation with the Alexa Fluor-647 goat anti-mouse IgG
(Invitrogen, Carlsbad, CA) for 30 min at 4uC. Fluorochrome-
and isotype-matched controls (eBioscience and BD Bioscience)
were used in parallel experiments to monitor nonspecific staining.
The cells were washed, resuspended, and filtered through a 40-mm
cell strainer. Propidium iodide was used to exclude nonviable cells.
CD34
+/M-cad
+ BMCs, CD34
+/M-cad
2 BMCs, and CD34
2/M-
cad
+ BMCs were isolated by using a FACSAir dual-laser
fluorescence cell sorter (BD Bioscience). In addition, phycoery-
thrin-conjugated rat anti-mouse isotype controls and phycoery-
thrin-conjugated antibodies, including IgG2a, IgG2b, CD31,
CD45, and CXCR4 (all from eBioscience), were used to examine
the surface antigen profile of CD34
+/M-cad
+ BMCs. Data were
recorded with a FACS LSRII (BD Biosciences) and analyzed by
FACSDiva software.
Reverse Transcription-Polymerase Chain Reaction
(RT-PCR)
RNA isolation was performed according to the protocol provided
by the manufacturer (RNeasy Plus Micro Kit, QIAGEN, German-
town, MD). The purity of RNA was estimated by the A260/A280
ratio (NanoDrop 1000 Spectrophotometer, Thermo Scientific,
Waltham, MA).Total RNAfrom sorted CD34
2/M-cad
2, CD34
+/
M-cad
2, CD34
2/M-cad
+, CD34
+/M-cad
+ BMC fractions
(C57BL6/J mice), C2C12 myoblast cell line (ATCC), human
Rh30 cell line (kindly provided by Dr. P. Houghton, Nationwide
Children’s Hospital), and human CD34
+ bone marrow mononu-
clear cells (Stem Cell Technologies, Vancouver, Canada) were
reverse transcribed with the oligo dT primer and superscript III first
strand synthesis system (Invitrogen). PCR was subsequently carried
out with CD34, M-cadherin and GAPDH (internal control) specific
primer pairs (Table S1) and platinum Taq DNA polymerase
(Invitrogen). The primers were designed by using Primer-Blast
provided by NCBI. The sizes of PCR products were determined by
comparison to a 100 bp DNA ladder (Invitrogen) under UV light
after 1–2% agarose gel electrophoresis.
Hematopoietic Progenitor Assays
CD34
+/M-cad
+ sorted cells were cultured using CollagenCult
Medium Kit (StemCell Technologies) per the manufacturer’s
protocol. The cells were suspended in a medium/collagen solution
containing cytokines (10 ng/mL interleukin-3, 10 ng/mL inter-
leukin-6, and 50 ng/mL SCF), and 2.2610
4 cells were seeded
onto tissue culture plates that were incubated under 5% CO2
(37uCa t$95% humidity). At 21 days, maximum colony size was
assessed, and colony-forming cells of the granulocyte/macrophage
lineages were identified by morphologic criteria. Collagen gels
CD34
+/M-cad
+ cells in hindlimb ischemia
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formed to identify cellular components.
Laser Doppler Perfusion Imaging
Blood flow in the ischemic (left) and nonischemic contralateral
(right) limb was measured by using a laser Doppler perfusion
image device (Perimed AB) as previously described [23], and blood
flow recovery was determined by comparing flow in the ischemic
to nonischemic limb in each mouse [26,27].
Arteriolar Density Analysis
Ischemic hindlimbs were decalcified 60 days after cell therapy.
Each hindlimb was transversely cut into 5 equal sections (proximal
to distal) and embedded in 5 separate paraffin blocks. Arterioles
were identified in 6-mm serially cut sections from each tissue block.
Sections were stained with a monoclonal antibody directed against
a-smooth muscle actin (a-SMA) (1:50 dilution; Sigma, clone 1A4).
Arterioles were identified as vessels that stained positive for a-SMA
and had an outer diameter of 10–30 mm. Sections were
counterstained with hematoxylin to identify nuclei. Arterioles
were counted in a blinded manner in 5 randomly selected high-
power fields (5206680 mm) at 206 magnification on transverse
sections from each hindlimb. Vessel densities were expressed as the
number of arterioles per square millimeter.
Immunofluorescence Studies
Cell-treated ischemic limbs were decalcified after harvesting at
various time points as described above. Frozen leg (treated with
2.5610
7 unselected GFP
+ BMCs for 7 days) cross-sections (6–
10 mm) were incubated with anti-M-cadherin antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) overnight at 4uC. Sections
were then incubated with Alexa Fluor-594 donkey anti-rabbit IgG
(Invitrogen, Carlsbad, CA). Nuclei were counterstained with
DAPI. Immunostained tissues were visualized with a Leica DM
LB fluorescent microscope (Meyer Instruments, Houston, TX).
Cryosections (6–10 mm) from hindlimbs (n=5, 20 sections/leg)
treated with 3610
5 GFP
+ CD34
+/M-cad
+ BMCs from animals
euthanized at 21 days were incubated with primary antibodies
against von Willebrand factor (vWF, Abcam), CD146 (Abcam), a-
SMA (Abcam), and/or laminin (Sigma). Tissue sections were then
incubated with Alexa Fluor-594 donkey anti-rabbit IgG, Alexa
Fluor-594 donkey anti-goat IgG, and/or Alexa Fluor-647 donkey
anti-rabbit IgG (all from Invitrogen). Nuclei were counterstained
with DAPI as above. The fluorescent images were obtained by
using a laser scanning confocal microscope (Olympus FV500).
Image processing, morphometry, and data analysis were per-
formed by using digital microscopic software SlideBook 5.0 (3i).
The correlation of fluorescence intensity in 1 channel with another
was measured by using Pearson’s correlation.
Immunohistochemistry
Paraffin-embedded limb sections (6-mm) of ApoE
2/2 mice (8–
12 months old; n=5) were deparaffinized, rehydrated, and stained
with a monoclonal antibody directed against a-SMA (Sigma).
Sections were counterstained with hematoxylin to identify nuclei.
Vascular images were taken with the use of an inverted light
microscope (Olympus IX71) and analyzed with Image-Pro Plus
software (Media Cybernetics).
Cytokine Array
Approximately 2610
5 CD34
+/M-cad
+ BMCs or CD34
+/M-
cad
2 BMCs were seeded in separate 10-mm culture dishes in
Iscove’s Modified Dulbecco’s Medium (IMDM, Invitrogen)
supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin for 24 hrs, and then changed to serum-
free IMDM for an additional 24 hrs. Conditioned medium was
collected, filtered to eliminate cell debris, and frozen at 280uC. A
cytokine array kit was used according to the manufacturer’s
instructions (RayBiotech, Inc., Norcross, GA). In short, after a
brief membrane blocking step, CM was added, and the membrane
was incubated overnight at 4uC. After a series of washes, the
membrane was incubated with biotinylated anti-cytokine antibod-
ies and horseradish peroxidase conjugated-streptavidin followed
by signal detection using ECL-Hyperfilm. Cytokine expression
levels were measured using ImageJ software and analyzed with
RayBio Analysis Tool S.09 (RayBiotech, Inc).
Tube and Network Formation Assay
Mouse BMCs were collected as previously described [23] and
sorted for CD34
+/M-cad
+ and CD34
+/M-cad
2 cells. Approxi-
mately 7610
5 CD34
+/M-cad
+ or CD34
+/M-cad
2 cells/well were
seeded in a 24-well plate with DMEM (10% FBS, 1% PS) and
incubated (37uC, 5% CO2) overnight. DMEM was then removed,
and serum-free DMEM was added to the wells and allowed to
incubate for an additional 48 hours. CD34
+/M-cad
+ or CD34
+/
M-cad
2 cell CM was collected and used to perform endothelial
tube formation assays.
A collagen-based reduced growth factor membrane matrix
(Geltrex
TM, Invitrogen) was coated (50 ml/cm
2) onto 24-well
plates. A thin-gel method was used to ensure endothelial cell
differentiation. The plates were then incubated for 30 minutes to
allow the gel to solidify. Afterward, approximately 3.5610
5
SVEC4-10 mouse endothelial cells (American Type Culture
Collection, Manassas, VA) were resuspended in 200 ml/cm
2 of
CD34
+/M-cad
+ CM or CD34
+/M-cad
2 CM with the addition of
1% FBS final concentration. SVEC4-10 cells were seeded into 24-
well plates and placed in an incubator (37uC, 20% O2 5% CO2)t o
allow tube formation to develop. Tube formation was documented
every hour until a pronounced difference between CD34
+/M-cad
+
or CD34
+/M-cad
2 cell CM group was observed. Additionally, we
performed the tube formation assay with SVEC4-10 cells under
hypoxic conditions (37uC, 1% O2,5 %C O 2). The cells were
placed in serum-free media for 24 hours in a hypoxia chamber
(Galaxy 14S, New Brunswick, Edison, NJ). After starvation, cells
were prepared as above, and tube formation was carried out in the
hypoxia chamber. Tube formation was documented at 4, 6, and
8 hours incubation.
Digital images were taken using an inverted light microscope
(Olympus IX71, Leeds Instruments, Irving, TX) at a 406
magnification for all assay conditions. Assays were performed in
triplicate; images were taken in 3 different microscopic fields/well,
and the total cumulative tube length (mm) was measured. Analysis
was performed by using NIH Image J software.
Statistical Analysis
Data were expressed as mean 6 standard error of mean (SEM).
One-way analysis of variance (ANOVA) with the Mann-Whitney
post hoc test was used to determine statistical significance within and
between groups (GraphPad Prism 5). P,0.05 was considered
statistically significant.
Results
Mouse Bone Marrow Contains a Population of
Double-Positive CD34
+/M-cad
+ Cells
To identify a subpopulation of BMCs that targets ischemic
tissues, unselected BMCs from GFP
+ mice were intraarterially
CD34
+/M-cad
+ cells in hindlimb ischemia
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2/2 mice. After 7
days, transverse sections of the ischemic hindlimbs were analyzed
by using immunofluorescence. A panel of antibodies was used to
detect engrafted cells derived from donated GFP
+ BMCs. During
these initial investigations, we found that GFP
+ cells that co-
expressed M-cadherin localized to the damaged tissue area, as
shown in Figure S1. Previously, we reported the detection of
donated GFP
+ BMCs co-expressing CD34 in treated ischemic
limbs [23].
After conducting immunostaining experiments to identify GFP
+
CD34
+ cells and GFP
+ M-cad
+ in the ischemic limbs of ApoE
2/2
mice following GFP
+ BMC treatment, we further investigated
CD34 and M-cadherin expression in bone marrow cells by flow
cytometry. To ensure specific and accurate detection, isotype- and
fluorochrome-matched controls to CD34 and M-cad antibodies
were used in parallel. Flow cytometric analysis of freshly isolated
viable BMCs (Fig. 1A and 1B) that were stained with M-cad
antibody (Fig. 1C) showed a small subpopulation of M-cad
+ cells
(5.3060.63%, n=4; Fig. 1C) as compared to those that stained
positive with mouse isotype control IgG2a (1.4260.29%). Analysis
also revealed an expected CD34
+ BMC population (8.8660.58%).
In addition, a distinct double-positive population of CD34
+/M-
cad
+ BMCs (4.2860.60%, Fig. 1D) was identified by flow
cytometry after costaining BMCs with CD34 and M-cad
antibodies. For additional validation, the expression of CD34
and M-cadherin on sorted CD34
+/M-cad
+ BMCs was confirmed
by RT-PCR. The mouse myoblast cell line, C2C12, known for
expressing both CD34 and M-cadherin [28], was used as a positive
control during RT-PCR (Fig. 1E). Furthermore, M-cadherin
expression in CD34
+ human bone marrow mononuclear cells
(BMMNCs) was studied by RT-PCR. Using specific human M-
cad primer pairs (Table S1), we detected a definite PCR product
indicating the existence of M-cad transcript in CD34
+ BMMNCs
(Fig. 1F). An M-cadherin–expressing human Rh30 cell line was
used as positive control [29]. Finally, immunophenotyping of
surface-antigen profile indicated that mouse CD34
+/M-cad
+
BMCs possess hematopoietic characteristics with high ($85%)
expression levels of CD45, CD31, and CXCR4 (Fig. S2).
The multipotent clonogenic potential of CD34
+/M-cadherin
+
BMCs population was examined in colony-forming unit (CFU)
assays. Figure 2 shows the proliferative potential and enriched
hematopoietic colony-forming activity (ie, CFU-G, CFU-M and
CFU-GM) of CD34
+/M-cadherin
+ BMCs grown in collagen-
based semi-solid medium supplemented with SCF, IL-3, and IL-6.
This finding suggests that this cell type is a hematopoietic
progenitor population with multilineage development capability.
Treatment With CD34
+/M-cad
+ Cells Significantly
Improves Recovery of Persistent Blood Flow in the
Ischemic Hindlimbs of ApoE
2/2 Mice
We compared the efficacy of sorted CD34
+/M-cad
+ BMCs to
that of CD34
+/M-cad
2 cells, CD34
2/M-cad
+ cells, and
unselected BMCs in restoring blood flow to ischemic hindlimbs.
Blood flow was measured before treatment, 30 minutes after
treatment, and every 7–10 days thereafter up to 60 days.
Representative laser Doppler images (Fig. 3A) illustrate perfusion
of the ischemic (left) legs versus the nonischemic contralateral
limbs. As early as 7 days after surgery, blood flow recovery was
better in mice treated with CD34
+/M-cad
+ BMCs than in any
other treatment group. Moreover, flow recovery was significantly
better in CD34
+/M-cad
+ BMC–treated mice than in mice
treated with CD34
+/M-cad
2 BMCs at 7 days (55.4464.31% vs
35.3864.32%; P,0.05; n=9–11; Fig. 3B). At 14 and 21 days,
the CD34
+/M-cad
+ BMC treatment group showed significantly
superior blood flow recovery over unselected BMCs (P,0.01). At
21 days, the CD34
+/M-cad
+ BMC treatment group showed
improvement over the CD34
2/M-cad
+ treatment group
Figure 1. Identification of CD34
+/M-cadherin
+ bone marrow progenitor cells. (A) Scatter plot of BMCs collected from C57BL6/J mice. The P1
gate was used to discriminate doublets. (B) BMC viability. Propidium iodium (PI) was used to exclude dead cells (PI
+ cells) from further analysis. (C)
Identification of M-cad
+ and CD34
+ subsets. Indirect staining with M-cadherin antibody revealed a small fraction of M-cad
+ BMCs compared with
isotype-and fluorochrome-matched controls. CD34
+ BMCs were detected by an FITC-conjugated anti-CD34 monoclonal antibody. (D) Identification of
a CD34
+/M-cadherin
+ subpopulation from freshly isolated BMCs. (E) RT-PCR analysis of CD34 and M-cadherin mRNA in sorted mouse BMC
subpopulations. (F) The detection of M-cadherin mRNA in human CD34
+ BMMNCs by RT-PCR.
doi:10.1371/journal.pone.0020673.g001
CD34
+/M-cad
+ cells in hindlimb ischemia
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+/M-cad
+ BMCs
showed significantly improved blood flow over CD34
+/M-cad
2
(P,0.05), CD34
2/M-cad
+ (P,0.05), and unselected (P,0.01)
BMCs at 40, 50, and 60 days. Furthermore, 10–30% of the mice
from the other treatment groups developed necrotic hindlimbs or
died within 60 days as compared with none in the CD34
+/M-
cad
+ cell treatment group (Table S2). These findings indicate
that CD34
+/M-cad
+ treatment reduced ischemia-related muscle
necrosis.
CD34
+/M-cad
+ Cell Therapy Results in Significantly Greater
Arteriogenesis in the Ischemic Legs of ApoE
2/2 Mice
Because neovascularization is believed to be essential for
maintaining perfusion recovery, we studied arteriogenesis after
cell therapy. To identify arteries and arterioloes, we immuno-
stained tissue sections of ischemic legs with a-SMA 60 days after
cell treatment. Arterioles (luminal size 10–30 mm) were quantified
in a blinded manner. We analyzed 408 sections from the 4
treatment groups (average, 105–130 sections/group; n=4) and
Figure 2. CD34
+/M-cad
+ BMCs give rise to hematopoietic progenitors. Representative photomicrographs of CD34
+/M-cad
+ BMCs reveal both
granulocytic and monocytic lineages (CFU-GM, CFU-G, and CFU-M). Top row, photomicrographs taken under inverted light microscope; bottom row,
May-Gru ¨nwald-Giemsa stain. Magnification: 406, CFU-GM and CFU-G; 1006, CFU-M.
doi:10.1371/journal.pone.0020673.g002
Figure 3. Recovery of blood flow in the ischemic limbs of ApoE
2/2mice treated with CD34
+/M-cad
+ BMCs. (A) Representative laser
Doppler perfusion images taken at indicated intervals for the 4 treatment groups (n=9–11/group). Blood perfusion in the ischemic hindlimbs was
markedly increased in the CD34
+/M-cad
+ BMC group compared with other cell treatment groups. IS=ischemic legs, NIS=nonischemic legs. (B)
Quantitative analysis of hindlimb blood perfusion. The increase in ischemic:nonischemic ratio was significantly higher in the CD34
+/M-cad
+ BMC
group compared with other treatment groups at multiple time points. Data are expressed as mean 6 SEM, n=9–11/group. *P,0.01, CD34
+/Mcad
+ vs
unselected BMC group;
#P,0.05, CD34
+/Mcad
+ vs CD34
+/Mcad
2;
{P,0.05, CD34
+/Mcad
+ vs CD34
2/Mcad.
+ Maximal blood flow perfusion was set at
1.0 compared to the contralateral leg after femoral artery ligation.
doi:10.1371/journal.pone.0020673.g003
CD34
+/M-cad
+ cells in hindlimb ischemia
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+/M-
cad
+–treated group compared to mice treated with CD34
+/M-
cad
2 cells, CD34
2/M-cad
+ cells, or unselected BMCs cells
(P,0.01, P,0.001, P,0.0001, respectively; Fig. 4). The identifi-
cation and our analysis of arterioles from 5 different anatomic
levels throughout the entire leg provide evidence of widespread
neovascularization promoted by treatment with CD34
+/M-cad
+
BMCs.
CD34
+/M-cad
+ BMCs Engraft into Solid Tissues and
Differentiate into Vascular Structures Under Ischemic
Conditions
To examine whether CD34
+/M-cad
+ progenitor cells incorpo-
rate into hindlimbs and differentiate into vascular cells, we
delivered a single dose of 3610
5 GFP
+ CD34
+/M-cad
+ BMCs into
the ischemic legs of ApoE
2/2 mice and euthanized the mice 21
days after cell delivery. Long-term engraftment of injected cells
was assessed histologically on transverse sections of cell-treated
legs. To measure the GFP
+ area (pixels/mm
2) in cross-sections of
leg samples, we masked the individual nuclei in entire laser
scanning confocal images of the specimen. Morphometric analysis
in combination with Pearson’s correlation was used to quantify the
colocalization of GFP expression with nuclei (DAPI) signals. We
determined that authentic GFP
+ cells incorporated into recipient
mouse legs (Fig. 5A). The same experimental analysis procedures
were applied to specimens treated with GFP
+ CD34
+/M-cad
2
cells (Fig. 5B). However, we observed considerable differences in
the distribution of GFP
+ cells in anatomic areas, partially due to
the delivery route (intrafemoral delivery of donor cells) and to a
low level of engraftment (,1%). Thus, we were unable to calculate
the accurate engraftment rate of donated GFP
+ cells. Despite the
limited incorporation of donated progenitor cells, confocal
microscopic examination of transverse leg sections followed by
CD146 (endothelial cell marker) or a-SMA staining revealed
vascular differentiation of transplanted GFP
+ CD34
+/M-cad
+ cells
in ischemic legs at 21 days (n=5). Donated GFP
+ CD34
+/M-cad
+
progenitors gave rise to endothelial and smooth muscle structures
in the muscle tissue of ApoE
2/2 mice (Fig. 6). Using confocal
microscopic analysis of cross-sections of limb muscular tissues
followed by immunofluorescence staining with the endothelial
marker vWF, we found colocalization of GFP with vWF signals
(Fig. 6), confirming the differentiation of GFP
+ CD34
+/M-cad
+
cells into endothelial cells. Thus, our data clearly demonstrated
that CD34
+/M-cad
+ progenitors can integrate into host structures
and serve as common vascular progenitors for postnatal
arteriogenesis. Although GFP
+ CD34
+/M-cad
+ cells integrated
into vascular structures, we were unable to find functional
arterioles or arteries that originated entirely from GFP
+ CD34
+/
M-cad
+ cells. Limited incorporation of GFP
+ CD34
+/M-cad
+ cells
into functional arterioles makes direct vascular differentiation of
this cell type into newly formed arterioles an unlikely major
mechanism that mediates arteriogenesis.
CD34
+/M-cad
+ BMCs Secrete a Unique Array of Cytokines
and Growth Factors
Since the benefits of adult stem/progenitor cell therapy,
including angiogenesis, arteriogenesis and vasculogenesis, are
mainly derived from the paracrine effects of transplanted cells
[17,19], we assessed and compared the in vitro release of cytokines
and growth factors by CD34
+/M-cad
+ and CD34
+/M-cad
2
BMCs. We quantified the secretion of multiple proangiogenic and
proliferative factors by using a cytokine antibody array (Fig. 7). Of
the 20 cytokines measured, basic fibroblast growth factor (bFGF),
epidermal growth factor (EGF), and insulin-like growth factor-1
(IGF-1) were significantly increased in the CM of CD34
+/M-cad
+
cells as compared to CM from CD34
+/M-cad
2 BMCs. Addition-
ally, CD34
+/M-cad
+ cells released significantly higher levels of Flt-
3 ligand (Flt-3L), a growth factor involved in survival, prolifera-
tion, and differentiation of early progenitor cells and endothelial
vessels [30]. Furthermore, the CM of CD34
+/M-cad
+ cells had
significantly higher levels of SDF-1, which along with its specific
receptor CXC chemokine receptor 4 (CXCR4), plays a critical
role in promoting progenitor cell trafficking, engraftment, and
angiogenesis [31,32]. Levels of CXCL-10 (CRG-2), which recruits
Figure 4. Significant arteriogenesis in ischemic limbs of ApoE
2/2 mice after treatment with CD34
+/M-cad
+ BMCs. ApoE
2/2 mice were
euthanized at 60 days after cell treatment. Transverse sections (6 mm) were immunostained against a-smooth muscle actin and counterstained with
hemotoxylin. (A) Representative photomicrographs of arterioles (arrows) in ischemic legs treated with the indicated cell type. Scale bar=50 mm. (B)
Summary of quantitative analysis of arteriole density in 4 treatment groups at 60 days after cell treatment. Values are mean 6 SEM, n=4/
group;*P,0.01, **P,0.001, ***P,0.0001.
doi:10.1371/journal.pone.0020673.g004
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+ CD34
+/M-cad
+ and GFP
+ CD34
+/M-cad
2 BMCs at 21 days after cell therapy. Representative confocal
micrographs and quantitative analysis show GFP
+ cells colocalized with DAPI in the ischemic legs of ApoE
2/2 mice treated with (A) GFP
+ CD34
+/M-
cad
+ BMCs and (B) GFP
+ CD34
+/M-cad
2 BMCs. N=5 ApoE
2/2 mice/cell treatment group. Scale bar=10 mm.
doi:10.1371/journal.pone.0020673.g005
Figure 6. Vascular development of GFP
+ CD34
+/M-cad
+ BMCs in the ischemic legs of ApoE
2/2 mice. ApoE
2/2 mice were euthanized 21
days after GFP
+ CD34
+/M-cad
+ cell therapy, and the cell-treated legs were processed. Immunofluroescence staining for CD146, a-SMA, and von
Willebrand Factor (vWF) was used to identify endothelial and smooth muscle cells that originated from GFP
+ CD34
+/M-cad
+ BMCs in cross-sections of
muscle tissue. (A, F, and J) Confocal images of muscle cross-sections showing the presence of GFP
+ cellular structures. (B, G, and K) CD146, a-SMA,
and vWF immunostaining. (C, H, and L) DAPI nuclei counterstaining. (D) Myofibers outlined by laminin staining. (E) Merged image of A, B, C, and D.
GFP
+ cells coexpressing CD146 are displayed in the insert. (I) Merged image of F, G, and H. GFP
+ cells colocalized with a-SMA as shown in the
enlarged image, indicating vasculature formation from transplanted cells. (M) Merged image of J, K, and L. Arrows indicate colocalization of GFP and
vWF-positive cells.
doi:10.1371/journal.pone.0020673.g006
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higher in CD34
+/M-cad
+ CM than in CM of CD34
+/M-cad
2
BMCs. Together, our results provide clear evidence that CD34
+/
M-cad
+ cells secrete a variety of prosurvival and proangiogenic
cytokines that can induce a functional vascular network.
Conditioned Medium from CD34
+/M-cad
+ Cells Enhances
Angiogenesis In Vitro Under Hypoxic Conditions
We used a common reliable tube formation assay to examine
the ability of CD34
+/M-cad
+ cells to drive angiogenesis of
endothelial cells in vitro. Nutrient-starved mouse endothelial cells
(SVEC4-10) incubated with CD34
+/M-cad
+ or CD34
+/M-cad
2
CM under normoxic conditions (20%O2, 5%CO2,3 7 uC)
effectively migrated towards each other, directionally aligned
themselves, and formed a complex tubular network as early as
4 hours after seeding on the matrix (Fig. 8A). However, the total
length of the tubes was significantly increased in endothelial cells
incubated with CD34
+/M-cad
+ CM when compared to tube
length in endothelial cells incubated with CD34
+/M-cad
2 CM
(Fig. 8C).
To further test the angiogenic effects of CD34
+/M-cad
+ CM
versus CD34
+/M-cad
2 CM during ischemia, we preconditioned
nutrient-starved mouse endothelial cells under hypoxic conditions
(1%O2,5 % C O 2,3 7 uC) for 24 hours prior to incubating them
with individual CM. In the presence of CD34
+/M-cad
+ or
CD34
+/M-cad
2 CM, tubular structures were created. However,
fewer capillary-like networks were formed and longer incubation
period were required as compared with endothelial cells treated
with the same CM during normoxia (Fig. 8B). Under hypoxic
conditions, the total tube length of endothelial cells treated with
CD34
+/M-cad
+ CM was significantly higher at 8 and 12 hours
than the tube length seen in endothelial cells treated with
CD34
+/M-cad
2 CM (Fig. 8D). These findings are consistent with
our in vivo results showing significant restoration of blood flow
perfusion and greater arteriogenesis in the ischemic legs of
ApoE
2/2 mice.
Figure 7. Increased cytokine secretion from CD34
+/M-cad
+ BMCs compared to CD34
+/M-cad
2 BMCs. (A) Representative membranes and
corresponding analysis key for CM from each indicated cell population. (B) CM from CD34
+/M-cad
+ BMCs showed significant secretion levels of key
stimulatory cytokines compared with CM from CD34
+/M-cad
2 BMCs. The cytokine arrays (n=3) were quantified by using the S.09 analysis tool
(RayBiotech, Inc). Data are expressed as mean 6 SEM. *P,0.05 vs CM of CD34
+/M-cad
2 BMCs. bFGF, basic fibroblast growth factor; CRG-2, cytokine
responsive gene-2; EGF, epidermal growth factor; Flt-3L, FMS-like tyrosine kinase-3 ligand; G-CSF, granulocyte colony stimulating factor; HGF,
hepatocyte growth factor; IGF-1, insulin-like growth factor-1; IL, interleukin; LIX, lipopolysaccharide inducible CXC chemokine; MCP-1, monocyte
chemoattractant protein-1, SCF, stem cell factor; SDF-1, stromal cell-derived factor-1; TIMP-2, tissue inhibitor of metalloproteinases-2; VEGF, vascular
endothelial growth factor.
doi:10.1371/journal.pone.0020673.g007
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We have identified a novel population of CD34
+/M-cad
+
hematopoietic progenitor cells in adult mouse bone marrow that
improved blood flow recovery better than CD34
+/M-cad
2 and
CD34
2/M-cad
+ cells in an atherosclerotic mouse model of PAD.
Significant blood flow recovery was maintained for up to 60 days
after CD34
+/M-cad
+ cell treatment. Furthermore, CD34
+/M-
cad
+ BMCs promoted uniform neoformation of arteriolar vessels
during a 60-day period. The pro-angiogenic property of CD34
+/
M-cad
+ cells was facilitated by their direct regeneration of
endothelial and smooth muscle cells in ischemic muscles. Multiple
Figure 8. CD34
+/M-cad
+ CM enhanced endothelial cell capillary tube network formation. (A) Serum-starved SVEC4-10 cells were mixed
with collagen matrix and incubated with CD34
+/M-cad
+ or CD34
+/M-cad
2 CM under normal (20%O2, 5%CO2,3 7 uC) conditions for 4 hours. (B)
Hypoxic (1%O2, 5%CO2,3 7 uC), serum-starved SVEC4-10 cells were mixed with collagen matrix and incubated with CD34
+/M-cad
+ -or CD34
+/M-cad
2
CM for up to 12 hrs. Timed-incubation revealed that capillary-like tube formation was greater in the CD34
+/M-cad
+ CM–treated group than in the
CD34
+/M-cad
2 CM–treated group. Scale bar=50 mm. (C) Quantification of tube length in SVEC4-10 cells after incubation with CD34
+/M-cad
2 or
CD34
+/M-cad
+ CM under normoxic conditions (n=3,***P,0.001 vs CD34
+/M-cad
2). (D) Quantification of tube length in SVEC4-10 cells at 4, 8, and
12 hours after incubation with CD34
+/M-cad
2 or CD34
+/M-cad
+ CM under hypoxic conditions (n=3, **P,0.01, ***P,0.001 vs CD34
+/M-cad
2). Total
tube length (mm) was reported as mean 6 SEM.
doi:10.1371/journal.pone.0020673.g008
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planted CD34
+/M-cad
+ cells may synergistically augment vascu-
logenic effects as well. Furthermore, we have shown the existence
of CD34
+/M-cad
+ population in human BMMNCs, making this
population a potential candidate for clinical use.
An animal model that resembles human PAD is crucial for
examining and validating the potential benefits of any novel cell
type in a preclinical study. PAD resulting from atherosclerosis
produces chronic ischemia. Mice that are deficient in apolipopro-
tein E (ApoE
2/2) develop spontaneous atherosclerosis that
narrows the vessel lumen, which leads to progressive restriction
of blood flow at multiple arterial branches [24,34,35]. Reddick
and colleagues analyzed in detail the age-dependent progressive
increase in atherosclerosis in ApoE
2/2 mice fed normal mouse
chow [24]. Complex, extensive atherosclerotic lesions (eg, foam
cells, cholesterol clefts, fibrous-cap lesions, and calcification) and
severe vessel occlusion were observed by 8 months of age. These
lesions were found not only in the aorta and the heart, but also in
the peripheral vessels, including the iliac arteries. Our findings
support those of Reddick and colleagues [24] in that we observed
spontaneous atheromas in the hindlimb vessels of 8–12–month-old
ApoE
2/2 mice (n=5) fed normal chow (Fig. S3). The athero-
sclerotic lesions had several histologic characteristics that signifi-
cantly narrowed or damaged the vessels (Fig. S3). Therefore, we
used 8–15–month-old ApoE
2/2 mice as cell therapy recipients
because they develop chronic atherosclerosis similar to the
atherosclerotic lesions seen in human [36,37].
CD34
+ BMCs have been shown in animal and human studies to
possess primitive hematopoietic and endothelial progenitor cell
potential [38,39,40,41]. M-cadherin belongs to the cadherin
multigene family of transmembrane glycoproteins [42]. As a
calcium-dependent cell adhesion molecule, M-cadherin is involved
in cell-cell communication and skeletal muscle development
[42,43]. Expression of M-cadherin and CD34 has been detected
in subsets of satellite cells that are able to repair injured muscle
[28,44]. Corti and colleagues isolated M-cad
+ BMCs from freshly
harvested mouse bone marrow cells that expressed myogenic
markers and showed myogenic potential after delivery into injured
muscle tissue [45]. Although the study by Corti and coauthors
focused on the potential repair of muscle injury by bone marrow-
derived myogenic cells, we demonstrated the beneficial effect of
CD34
+/Mcad
+ BMCs in the treatment of hindlimb ischemia via
the enhancement of neovascularization. The myogenic potential of
CD34
+/M-cad
+ BMCs should be further studied as our ultimate
goal is to apply cell therapy to promote angiogenesis and
myogenesis concomitantly in the ischemic limbs.
In this study, we demonstrated the superior ability of CD34
+/
M-cad
+ BMCs to enhance postischemic arteriogenesis compared
to CD34
+/M-cad
2 BMCs, CD34
2/M-cad
+ BMCs, and unselect-
ed BMCs. The comprehensive physiologic role of CD34
+/M-cad
+
BMCs may contribute to their direct vascular differentiation and
their trophic effect on intrinsic stem cell activation. Evidence
indicates that BMCs produce an array of proinflammatory
cytokines and proangiogenic factors capable of enhancing
angiogenesis [18]. In the present study, we found significantly
higher levels of growth factors, including bFGF, EGF, and IGF-1,
in the CM of CD34
+/M-cad
+ BMCs than in the CM of CD34
+/
M-cad
2. Moreover, higher levels of bFGF were released by
CD34
+/M-cad
+ BMCs than by CD34
+/M-cad
2 BMCs (Fig. 7B),
suggesting that bFGF may contribute to the differential therapeu-
tic effects observed with CD34
+/M-cad
+ cells. EGF, another well-
described growth factor, is noted for its vasculogenic influence on
stem cells. Kilroy and colleagues found that stem cells supple-
mented with EGF doubled their secretion of HGF in a synergistic
fashion to promote additional growth and cellular precondition-
ing, helping to minimize damage after ischemic injury [46]. IGF-1
has been shown to enhance muscle regeneration by activating
myogenic stem/progenitor cells [47,48]. Sustained dual delivery of
IGF-1 and the proangiogenic factor VEGF into ischemic
hindlimbs resulted in a synergistic effect on angiogenesis and
myogenesis [49]. Our results also suggest the beneficial interplay
among cytokines secreted by CD34
+/M-cad
+ BMCs. The
preferential release of IGF-1 and proangiogenic factors (eg, bFGF)
may account for the persistent vascular effects in the ischemic legs
of ApoE
2/2 mice.
In addition to those described above, we found that CD34
+/M-
cad
+ progenitor cells released several unique angiogenic and
vasculogenic cytokines. The CM of CD34
+/M-cad
+ cells showed
significant levels of Flt-3L, a tyrosine kinase associated with
stimulation of early hematopoietic cell differentiation [30].
Furthermore, we found that the stimulatory cytokines SDF-1
and CXCL-10 (CRG-2) were also significantly increased in the
CM of CD34
+/M-cad
+ BMCs compared to those of CD34
+/M-
cad
2 CM. CXCL-10 (CRG-2) stimulates the migration and
recruitment of MSCs [33]. A significant release of CXCL-10 by
CD34
+/M-cad
+ BMCs may help recruit endogenous MSCs from
the bone marrow to assist in the recovery of blood flow and
synergize with cytokines to promote arteriogenesis. Interestingly,
the soluble form of VEGFR3 (sVEGFR3) was markedly
upregulated in our cytokine analysis of the CM of CD34
+/M-
cad
+ BMCs. VEGF receptor3 (VEGFR3) is expressed in lymphatic
vessels under physiologic conditions [50]. sVEGFR3 inhibits
VEGFR3 signaling by binding to its ligands, VEGF-C and VEGF-
D, which results in a reduction of lymphangiogenesis [51]. In a
model of transgenic mice expressing sVEGFRs, Makinen and
colleagues showed that the effect of sVEGFR3 was specific to the
lymphatic vessels and did not affect the blood vessel network [51].
In animal tumor models, overexpression of VEGFR3 has been
found in tumor metastasis. By inhibiting VEGF-C and VEGF-D
signaling, sVEGFR3 sustained tumor growth and suppressed
metastasis formation [52]. Our array analysis showed a higher
secretion of sVEGFR3 (although at a low total level) by CD34
+/
M-cad
+ cells than by CD34
+/M-cad
2 cells; considering our array
profile data, this finding may indicate that the delicate balance of a
cocktail of factors released by progenitor cells is vital for promoting
therapeutic arteriogenesis and preventing malignant growth.
Further examination of paracrine-mediated arteriogenesis may
lead to enhanced strategies for cell therapy.
The aim of the present study was not to assess the benefit of a
single factor secreted by CD34
+/M-cad
+ cells, but rather to
examine whether the pleiotropic activity of this population can
enhance vascular repair and new vessel growth in ischemic tissue.
The novelty and advantage of using CD34
+/M-cad
+ cells is due to
their vascular differentiation capability, their secretion of a distinct
combination of angiogenic and myogenic factors, their ability to
rescue compromised cells in a hypoxic environment, and their
substantial in vivo neovascularization capacity. These beneficial
effects position CD34
+/M-cad
+ cells as an optimal cell type for
treating ischemic vascular diseases such as PAD, where local cells
are oxygen- and nutrient-deprived from the shortage of blood.
Because our cytokine array was restricted to the simultaneous
measurement of only 20 cytokines in CD34
+/M-cad
+ cell
supernatant, a large-scale study may uncover additional proangio-
genic cytokines.
In conclusion, we have described a novel adult subpopulation of
BMCs–CD34
+/M-cad
+cells–that promotes widespread arteriolar
growth and persistent blood flow recovery in the ischemic
hindlimbs of immunocompetent ApoE
2/2 mice. This population
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PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e20673displays hematopoietic proliferative potential, gives rise to vascular
cells, secretes a unique pattern of cytokines and growth factors,
and can significantly stimulate angiogenesis in nutrient- and
oxygen-depleted endothelial cells under hypoxic conditions. Our
results provide evidence that CD34
+/M-cad
+ cells can protect
against ischemic injury and may be a suitable candidate for use in
cell therapy against PAD.
Supporting Information
Figure S1 Identification of M-cad
+ BMCs in the ische-
mic legs of ApoE
2/2 mice injected with GFP
+ BMCs. (A)
Immunostaining for M-cad in engrafted cells, 7 days after
intraarterial injection of unselected GFP
+ BMCs. (B) DAPI
counterstaining. (C) Merged image of A and B. Scale bar=20 mm.
N=5 ApoE
2/2 mice.
(TIF)
Figure S2 Flow cytometric characterization of the
surface antigens of CD34
+/M-cad
+ BMCs. Representative
analysis figures show high expression levels of CD31, CXCR4,
and CD45 in CD34
+/M-cad
+ BMCs.
(TIF)
Figure S3 Atherosclerosis in hindlimb vessels of
ApoE
2/2 mice. Representative a-smooth muscle actin immu-
nostaining images reveal spontaneous atherosclerotic lesions
(indicated by arrows) in the hindlimb arteries of ApoE
2/2 mice
(8–12 months old). (A) Plaque within the peripheral artery. (B)
Medial hypertrophy. Enlarged images are shown in boxes.
(TIF)
Table S1 Primers used for RT-PCR.
(TIF)
Table S2 Clinical symptoms in ApoE2/2 mice after
cell therapy.
(TIF)
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